
EPRX Stock Forecast & Price Target
EPRX Analyst Ratings
Bulls say
Eupraxia Pharmaceuticals is positioned for upside because its DiffuSphere platform has already shown durable, localized drug delivery across two tissue environments, while EP-104GI’s open-label data suggest ~80% clinical remission at 6 months, 64% remission at 52 weeks in evaluable patients, and a clean safety profile with zero candidiasis, zero adrenal suppression, and no serious drug-related adverse events across 275+ patient-months. The upcoming December randomized Phase 2b RESOLVE interim readout is the key near-term catalyst, especially because the company has completed enrollment of 120 patients and ended 3Q26 with $126.4M in cash and short-term investments, providing runway into 2H28. Fundamentally, the stock appeal rests on a large, undertreated EoE market, differentiated once-yearly dosing, and a commercial model that could be supported by strong physician interest, practical endoscopy workflow fit, and meaningful reimbursement economics.
Bears say
Eupraxia Pharmaceuticals is a clinical-stage, pre-revenue biotech with no approved products, no revenue, and an accumulated deficit of $196.7MM as of June 30, 2026, so its valuation depends almost entirely on uncertain clinical success. Its lead program, EP-104GI, faces a high-stakes first vehicle-controlled readout after only open-label data from n=31, while management expects at least one Phase 3 study and further capital to be required, creating meaningful dilution risk. Commercially, the company is boxed in by powerful competition from dupilumab and tezepelumab, a $6,200 to $109,000 EoE pricing spectrum, endoscopy-based adoption barriers, and license economics that include up to 4% royalties and 20% of monetization proceeds at the current stage.
This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
EPRX Analyst Forecast & Price Prediction
Start investing in EPRX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast
EPRX Analyst Forecast & Price Prediction
Start investing in EPRX
Order type
Buy in
Order amount
Est. shares
0 shares